Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Emmanuel Gage

Interventional Pain Medicine Brunswick, GA Medical Doctor

NPI 1720213093 CMS profile 32759

3408 Trout St, Brunswick, GA 31520

Open in the dashboard

General payments

$601,780

1,206 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$46,267 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Emmanuel Gage of Brunswick, GA is reported in the CMS Open Payments database as having received $601,780 across 1,206 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $46,267 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $153,283 303
2024 General $81,039 207
2023 General $104,451 189
2022 General $121,832 196
2021 General $43,332 109
2020 General $54,585 99
2019 General $43,257 103

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Emmanuel Gage
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Emmanuel Gage were reported at $153,283. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Emmanuel Gage Interventional Pain Medicine median Middle half National median
2019 $43,257 $684 $216–$2,079 $163
2020 $54,585 $382 $122–$1,109 $114
2021 $43,332 $552 $167–$1,554 $132
2022 $121,832 $605 $187–$1,924 $149
2023 $104,451 $671 $195–$1,915 $160
2024 $81,039 $684 $206–$1,837 $164
2025 $153,283 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $417,420 888 payments
  2. SI-BONE, Inc. $101,968 112 payments
  3. Vertos Medical, Inc. $50,273 61 payments
  4. Vertiflex, Inc. $18,603 40 payments
  5. Alevio, LLC $5,785 5 payments
  6. Painteq LLC $2,436 18 payments
  7. Genesys Orthopedics Systems, L.L.C. $2,340 2 payments
  8. Intelivation Technologies, LLC $500 1 payment
  9. Abbott Laboratories $490 7 payments
  10. Medtronic, Inc. $470 17 payments
  11. Other $1,496 55 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $351,519 165 payments
  2. Consulting Fee $163,766 69 payments
  3. Travel and Lodging $51,490 200 payments
  4. Food and Beverage $33,505 771 payments
  5. Education $1,500 1 payment
Products named General payments · program years 2019–2025
  1. IFUSE IMPLANT SYSTEM $101,279 97 payments
  2. WaveWriter Alpha Prime 16 $84,514 340 payments
  3. Superion Indirect Decompression System Vertiflex Superion_NMD $75,625 109 payments
  4. mild Device Kit $50,259 60 payments
  5. SPECTRA WAVEWRITER $46,165 75 payments
  6. Superion Indirect Decompression System Pain Management $19,609 6 payments
  7. General - Therapies $18,736 18 payments
  8. Superion ISS $18,603 40 payments
  9. WAVEWRITER ALPHA $17,332 28 payments
  10. Superion $17,199 25 payments
  11. Other $64,660 285 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

6,114

Median for Interventional Pain Management: 1,220

Drug cost

$127,562

Median for Interventional Pain Management: $39,344

Branded share of claims

44.8%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,911 $41,123
Belbuca Buprenorphine Hcl Brand 49 $28,620
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 674 $14,057
Pregabalin Generic 549 $8,996
Gabapentin Generic 487 $6,313
Tizanidine Hcl Generic 422 $4,950
Buprenorphine Generic 14 $4,062
Oxycodone Hcl Generic 245 $3,541
Tramadol Hcl Generic 400 $2,233
Diclofenac Sodium Generic 168 $2,127

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 70 billing codes

Paid by Medicare

$1,050,726

Of which drugs: $3,278

Medicare patients

802

Average age 73

Services billed

31,513

490 women, 312 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 36%
Ischemic heart disease 30%
Chronic kidney disease 26%
Depression 24%
Osteoporosis 21%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 214 13,576 $1,389
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 506 13,543 $1,207
Injection, methylprednisolone acetate, 40 mg J1030 Office 98 129 $604
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 14 80 $63

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
$16 — —
EVENITY
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

1,206 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record